vida: extract claims from 2026-xx-pubmed-glp1-micronutrient-nutritional-deficiencies-narrative-review

- Source: inbox/queue/2026-xx-pubmed-glp1-micronutrient-nutritional-deficiencies-narrative-review.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-therapy-produces-population-scale-nutritional-deficiency-epidemic-with-minimal-monitoring.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: "The majority of GLP-1 users consume below recommended levels for iron (64%) and calcium (72%), creating a systematic nutritional safety crisis at the scale of millions of prescriptions"
+confidence: likely
+source: "Urbina et al. 2026, n=461,382 cohort for 22% deficiency rate; prospective pilot n=51 for iron absorption mechanism"
+created: 2026-04-11
+title: "GLP-1 receptor agonist therapy produces a population-scale nutritional deficiency epidemic affecting 22% of users within 12 months while 92% receive no dietitian support"
+agent: vida
+scope: causal
+sourcer: Urbina et al., PubMed 2026
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# GLP-1 receptor agonist therapy produces a population-scale nutritional deficiency epidemic affecting 22% of users within 12 months while 92% receive no dietitian support
+
+A large cohort study (n=461,382) found that 22% of GLP-1 receptor agonist users developed nutritional deficiencies within 12 months of starting treatment. The deficiency profile is severe: 64% of GLP-1RA users consumed less than the estimated average requirement for iron, 72% consumed below the recommended dietary allowance for calcium, and 58% did not meet protein intake targets. Vitamin D deficiency progressed from 7.5% at 6 months to 13.6% at 12 months. The mechanism is dual: GLP-1 suppresses appetite broadly (patients eat less food overall, not just less fat), and delayed gastric emptilation may alter micronutrient absorption—a prospective pilot (n=51) showed intestinal iron absorption dropped markedly after 10 weeks of semaglutide. The implementation gap is critical: 92% of patients had not visited a dietitian in the 6 months prior to GLP-1 prescription. At current US prescription volumes (millions of users), this represents a population-level nutritional safety signal that is not being systematically monitored. The deficiency risk compounds in patients with already-low baseline micronutrient levels, which is common in obesity and food insecurity populations—exactly the groups with highest metabolic disease burden and GLP-1 prescription rates.